Showing results (21-30 of 27) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Blood Advances|July 11, 2019
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota compositionMatthew J Pianko, Sean M Devlin, Eric R Littmann, et al.American Journal of Hematology|January 2, 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approachMatthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.Research Square|June 17, 2024
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple MyelomaMalin Hultcrantz, Hani Hassoun, Neha Korde, et al.Clinical Lymphoma, Myeloma & Leukemia|December 12, 2025
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup AnalysesHans C Lee, Jeffrey A Zonder, Madhav V Dhodapkar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2024
Linvoseltamab for Treatment of Relapsed/Refractory Multiple MyelomaNaresh Bumma, Joshua Richter, Sundar Jagannath, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2022
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based DietsUrvi A Shah, Kylee H Maclachlan, Andriy Derkach, et al.The New England Journal of Medicine|June 15, 2026
Talquetamab-Daratumumab in Relapsed or Refractory MyelomaRoberto Mina, Meral Beksac, Paula Rodríguez-Otero, et al.Pageof 3